CSPC Innovation Pharmaceutical (300765) Fundamentals 2026 — Revenue Analysis | SniperIQ
CSPC Innovation Pharmaceutical (300765) is a CN-listed Consumer Defensive company in Packaged Foods with a market capitalization of ¥55.8B, trading at ¥39.74 on the SHZ. This SniperIQ fundamentals page covers CSPC Innovation Pharmaceutical's valuation, profitability (net margin -13.1%), revenue (¥2.1B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is CSPC Innovation Pharmaceutical's market cap?
CSPC Innovation Pharmaceutical (300765) has a market capitalization of approximately ¥55.8B, trading at ¥39.74 on the SHZ. Market cap moves with the live share price.
What is CSPC Innovation Pharmaceutical's P/E ratio?
CSPC Innovation Pharmaceutical's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 21.5x. Valuation multiples are best compared with Consumer Defensive sector peers rather than read in isolation.
How profitable is CSPC Innovation Pharmaceutical?
CSPC Innovation Pharmaceutical runs a net profit margin of -13.1%, a gross margin of 37.4%, and an operating margin of -23.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does CSPC Innovation Pharmaceutical generate?
CSPC Innovation Pharmaceutical reported revenue of ¥2.1B for fiscal year 2025, with net income of -¥241M and earnings per share (EPS) of -0.17. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does CSPC Innovation Pharmaceutical pay a dividend?
CSPC Innovation Pharmaceutical does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is CSPC Innovation Pharmaceutical financially healthy?
CSPC Innovation Pharmaceutical carries a debt-to-equity ratio of 0.04x and a current ratio of 1.00x, with a market beta of 0.10. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is CSPC Innovation Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For CSPC Innovation Pharmaceutical (300765) the key facts are: market cap ¥55.8B, revenue ¥2.1B, 52-week range 22.5-60. Weigh valuation, profitability, growth, and balance-sheet strength against Consumer Defensive peers and form your own view.
Track CSPC Innovation Pharmaceutical's full fundamentals live
Get CSPC Innovation Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.